CRIS | Curis, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7990 - 2.1220
52 Week Range	1.0200 - 16.99
Beta	3.28
Implied Volatility	546.23%
IV Rank	33.78%
Day's Volume	69,568
Average Volume	58,678
Shares Outstanding	10,462,200
Market Cap	22,075,242
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-08-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.31
Forward P/E Ratio	-3.86
EPS	-6.88
1YR Price Target	17.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	USA
Website	CRIS

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

CRIS's peers: ARTL, ALRN, HSTO, TMBR, XFOR, MREO, INZY, TERN, LPTX, DAWN, PDSB, ADAP, PIRS, AFMD, CRVS, APTO

*Chart delayed

Analyzing fundamentals for CRIS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see CRIS Fundamentals page.

Watching at CRIS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CRIS Technicals page.